[144] NewAmsterdam Pharma Company N.V. Warrant SEC Filing

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. (NAMSW) reported a Form 144 notice showing a proposed sale of 18,073 ordinary shares (nominal value EUR 0.12) with an aggregate market value of $434,655.65 to be executed through Cooperatieve Rabobank U.A. on the Nasdaq Global Market on 09/03/2025. The shares were acquired on 09/02/2025 via an option exercise from NewAmsterdam Pharma Company N.V., paid in cash. The filer also reported a prior sale of 8,269 shares on 08/25/2025 generating $205,547.82. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Insider exercised options and is selling a small position worth ~$435k; transaction size is immaterial to total shares outstanding.

The sale of 18,073 shares for $434,655.65 represents a very small fraction of the issuers outstanding share base (112,628,458 shares). The shares were acquired one day prior via option exercise and immediately designated for sale, indicating a liquidity event by the holder rather than a large-scale dilution or financing. From an analytical standpoint, this transaction is routine and unlikely to materially affect valuation or capital structure given the relative size.

Corporate Governance Expert

TL;DR: Form 144 is a standard compliance disclosure for proposed insider sales; no disclosure of undisclosed adverse information.

The filing meets Rule 144 notice requirements by identifying the broker, class of shares, acquisition details (option exercise on 09/02/2025), and planned sale date (09/03/2025). The seller affirms no knowledge of material nonpublic information. The presence of a recent sale on 08/25/2025 is noted, which may be relevant for aggregation under Rule 144 but, based on reported volumes and proceeds, does not appear to trigger material governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, nominal value EUR 0.12 per share	Cooperatieve Rabobank U.A. Croeselaan 18 Utrecht P7 3521 CB	18073	434655.65	112628458	09/03/2025	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, nominal value EUR 0.12 per share	09/02/2025	Option Exercise	NewAmsterdam Pharma Company N.V.			18073	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Louise Kooij Gooimeer 2-35 Naarden P7 1411 DC	Ordinary shares, nominal value EUR 0.12 per share	08/25/2025	8269	205547.82

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did NewAmsterdam Pharma (NAMSW) disclose in this Form 144?

The filing shows a proposed sale of 18,073 ordinary shares valued at $434,655.65, to be sold on 09/03/2025 via Cooperatieve Rabobank U.A. on the Nasdaq Global Market.

How were the shares being sold acquired?

The shares were acquired on 09/02/2025 through an option exercise from NewAmsterdam Pharma Company N.V., with payment in cash on the same date.

Has the filer sold other NAMSW shares recently?

Yes, the filer sold 8,269 shares on 08/25/2025 for gross proceeds of $205,547.82.

What exchange and broker are involved in the proposed sale?

The proposed sale lists Cooperatieve Rabobank U.A. as the broker and the Nasdaq Global Market as the exchange.

Does the filing state any undisclosed material information about the company?

The seller represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.